205 related articles for article (PubMed ID: 30429879)
1. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.
Brendel M; Jaworska A; Overhoff F; Blume T; Probst F; Gildehaus FJ; Bartenstein P; Haass C; Bohrmann B; Herms J; Willem M; Rominger A
Theranostics; 2018; 8(18):4957-4968. PubMed ID: 30429879
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment.
Brendel M; Jaworska A; Herms J; Trambauer J; Rötzer C; Gildehaus FJ; Carlsen J; Cumming P; Bylund J; Luebbers T; Bartenstein P; Steiner H; Haass C; Baumann K; Rominger A
Mol Psychiatry; 2015 Oct; 20(10):1179-87. PubMed ID: 26055427
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease.
Deleye S; Waldron AM; Verhaeghe J; Bottelbergs A; Wyffels L; Van Broeck B; Langlois X; Schmidt M; Stroobants S; Staelens S
J Nucl Med; 2017 Dec; 58(12):1977-1983. PubMed ID: 28611242
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
[TBL] [Abstract][Full Text] [Related]
5. BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.
Peters F; Salihoglu H; Rodrigues E; Herzog E; Blume T; Filser S; Dorostkar M; Shimshek DR; Brose N; Neumann U; Herms J
Acta Neuropathol; 2018 May; 135(5):695-710. PubMed ID: 29327084
[TBL] [Abstract][Full Text] [Related]
6. AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice.
Eketjäll S; Janson J; Jeppsson F; Svanhagen A; Kolmodin K; Gustavsson S; Radesäter AC; Eliason K; Briem S; Appelkvist P; Niva C; Berg AL; Karlström S; Swahn BM; Fälting J
J Neurosci; 2013 Jun; 33(24):10075-84. PubMed ID: 23761903
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.
Jacobsen H; Ozmen L; Caruso A; Narquizian R; Hilpert H; Jacobsen B; Terwel D; Tanghe A; Bohrmann B
J Neurosci; 2014 Aug; 34(35):11621-30. PubMed ID: 25164658
[TBL] [Abstract][Full Text] [Related]
8. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
Rominger A; Brendel M; Burgold S; Keppler K; Baumann K; Xiong G; Mille E; Gildehaus FJ; Carlsen J; Schlichtiger J; Niedermoser S; Wängler B; Cumming P; Steiner H; Herms J; Haass C; Bartenstein P
J Nucl Med; 2013 Jul; 54(7):1127-34. PubMed ID: 23729696
[TBL] [Abstract][Full Text] [Related]
10. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal evaluation of a novel BChE PET tracer as an early
Rejc L; Gómez-Vallejo V; Joya A; Moreno O; Egimendia A; Castellnou P; Ríos-Anglada X; Cossío U; Baz Z; Passannante R; Tobalina-Larrea I; Ramos-Cabrer P; Giralt A; Sastre M; Capetillo-Zarate E; Košak U; Knez D; Gobec S; Marder M; Martin A; Llop J
Theranostics; 2021; 11(13):6542-6559. PubMed ID: 33995675
[No Abstract] [Full Text] [Related]
12. The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease.
Liang ZM; Peng YH; Chen Y; Long LL; Luo HJ; Chen YJ; Liang YL; Tian YH; Li SJ; Shi YS; Zhang XM
Nucleic Acid Ther; 2019 Dec; 29(6):359-366. PubMed ID: 31513457
[TBL] [Abstract][Full Text] [Related]
13. [
Stenzel J; Rühlmann C; Lindner T; Polei S; Teipel S; Kurth J; Rominger A; Krause BJ; Vollmar B; Kuhla A
Curr Alzheimer Res; 2019; 16(1):49-55. PubMed ID: 30345916
[TBL] [Abstract][Full Text] [Related]
14. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
[TBL] [Abstract][Full Text] [Related]
15. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition.
Schelle J; Häsler LM; Göpfert JC; Joos TO; Vanderstichele H; Stoops E; Mandelkow EM; Neumann U; Shimshek DR; Staufenbiel M; Jucker M; Kaeser SA
Alzheimers Dement; 2017 Jun; 13(6):701-709. PubMed ID: 27750032
[TBL] [Abstract][Full Text] [Related]
16. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
Hook G; Hook V; Kindy M
J Alzheimers Dis; 2011; 26(2):387-408. PubMed ID: 21613740
[TBL] [Abstract][Full Text] [Related]
17. Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
Thakker DR; Sankaranarayanan S; Weatherspoon MR; Harrison J; Pierdomenico M; Heisel JM; Thompson LA; Haskell R; Grace JE; Taylor SJ; Albright CF; Shafer LL
J Neurosci; 2015 Apr; 35(17):6931-6. PubMed ID: 25926467
[TBL] [Abstract][Full Text] [Related]
18. Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice.
Janssens J; Hermans B; Vandermeeren M; Barale-Thomas E; Borgers M; Willems R; Meulders G; Wintmolders C; Van den Bulck D; Bottelbergs A; Ver Donck L; Larsen P; Moechars D; Edwards W; Mercken M; Van Broeck B
Neurobiol Dis; 2021 Jul; 154():105365. PubMed ID: 33848635
[TBL] [Abstract][Full Text] [Related]
19. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease.
Devi L; Ohno M
Transl Psychiatry; 2013 Jul; 3(7):e284. PubMed ID: 23880880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
